ArticleFrontiers in oncology2025
Oral microbiome components predict response to neoadjuvant chemotherapy in triple-negative breast cancer patients.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Disease- and chemotherapy-associated salivary microbiome changes in breast cancer patients.Breast cancer research and treatment · 2026Article
- Oral Microbiota and Clinical Outcomes in Allogenic Hematopoietic Stem Cell Transplantation: A Systematic Review.Microorganisms · 2026Review
- Editorial: Understanding oral health challenges in pediatric and adult cancer care.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The oral microbiome has emerged as a critical biomarker and regulator in cancer development and treatment response, garnering increasing attention from researchers. However, its specific role in breast cancer, particularly in triple-negative breast cancer (TNBC), remains poorly understood. The influence of the oral microbiome on chemotherapy sensitivity in TNBC, along with the underlying molecular mechanisms, remains unclear. Further investigation is needed to assess its potential as a biomarker for predicting chemotherapy sensitivity in this patient population. In the present study, significant differences in the composition of the oral microbiome were observed among patients with varying chemotherapy sensitivities for TNBC patients. Additionally, notable changes in the oral microbiome were noted after chemotherapy in patients with favorable responses to treatment. Our analysis revealed that chemotherapy-sensitive patients had higher levels of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.